Dr. William (Billy) E. Cohn M.D. serves as Independent Director of the Company. Dr. Cohn has been a member of our Board since February 2015. Dr. Cohn is a Vice President of Medical Devices and Director of the Center for Device Innovation at Johnson & Johnson. He is also a Cardiothoracic Surgeon and a professor of Surgery at Baylor College of Medicine. Dr. Cohn is the chief medical officer of BiVACOR USA, a privately-held medical device company. In addition to being the only physician on our Board, we believe Dr. Cohn’s active involvement in the development, implementation, and regulatory clearance for several medical devices in cardiovascular medicine make him a valuable contributor to our Board and mission.
As the Independent Director of Cardiovascular Systems, the total compensation of William Cohn at Cardiovascular Systems is $200,000. There are 16 executives at Cardiovascular Systems getting paid more, with Scott Ward having the highest compensation of $4,718,960.
William Cohn is 60, he's been the Independent Director of Cardiovascular Systems since 2015. There are 5 older and 18 younger executives at Cardiovascular Systems. The oldest executive at Cardiovascular Systems Inc. is Augustine Lawlor, 64, who is the Independent Director.
William's mailing address filed with the SEC is 1225 OLD HIGHWAY 8 NW, , ST. PAUL, MN, 55112.
Over the last 16 years, insiders at Cardiovascular Systems have traded over $72,999,461 worth of Cardiovascular Systems stock and bought 949,532 units worth $8,687,068 . The most active insiders traders include Capital Management Lp Camber, Augustine Lawlor oraz Capital Ltdmaverick Capital.... On average, Cardiovascular Systems executives and independent directors trade stock every 14 days with the average trade being worth of $338,920. The most recent stock trade was executed by Martha Goldberg Aronson on 15 August 2022, trading 2,411 units of CSII stock currently worth $48,220.
Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease. The company's orbital atherectomy system treats calcified and fibrotic plaque in arterial vessels throughout the leg and heart and addresses many of the limitations associated with existing surgical, catheter and pharmacological treatment alternatives.
Cardiovascular Systems executives and other stock owners filed with the SEC include: